The User's Guide to Amivantamab.

Target Oncol · 2025 · PMC11933153 · PMID 39903428

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

Interim analysis showed a favorable trend toward OS benefit in amivantamab plus lazertinib (hazard ration (HR) 0.77; 95% CI 0.61–0.96) [ 26 ].

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.